1,314
Views
2
CrossRef citations to date
0
Altmetric
Oncology

Cost analysis of leuprorelin acetate in Japanese pre-menopausal breast-cancer patients: comparison between 6-month and 3-month depot formulations

, , , , &
Pages 1163-1169 | Received 30 Mar 2017, Accepted 15 Jul 2017, Published online: 16 Aug 2017

References

  • Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev 2015;25:1-12
  • Park W. Breast cancer role of ovarian function suppression in premenopausal women with early breast cancer. J Breast Cancer 2016;19:341-8
  • Anders CK, Johnson R, Litton J, et al. Breast cancer before age 40 years. Semin Oncol 2009;36:237-49
  • Goel S, Sharma R, Hamilton A, et al. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database of Systematic Reviews 2009;4:CD004562
  • Del Mastro L, Levaggi A, Giraudi S, et al. Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: Current role and future perspectives. Cancer Treat Rev 2011;37:208-11
  • Sethi R, Sanfilippo N. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer. Clin Interv Aging 2009;4:259-67
  • Kurebayashi J, Toyama T, Sumino S, et al. Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative. Breast Cancer 2017;24:161-70
  • Goto R, Uda A, Hiroi S, et al. Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: Comparison between 6-month and 3-month depot formulations. J Med Econ 2017;20:1155-62
  • Social Insurance Laboratory. Interpretation of Medical Fee Schedule Table. Tokyo (Japan): Social Insurance Laboratory Co. Ltd; 2016 (Japanese)
  • Japanese basic survey on wage structure on 2016 (In Japanese) [Internet]. Tokyo (Japan): Ministry of Health, Labour and Welfare; [cited 2017 Feb 24]. Available from: http://www.mhlw.go.jp/toukei/itiran/roudou/chingin/kouzou/z2015/dl/13.pdf/
  • Statistical classification of diseases and cause of death (In Japanese) [Internet]. Tokyo (Japan): Ministry of Health, Labour and Welfare; [cited 2017 Feb 24]. Available from: http://www.mhlw.go.jp/toukei/sippei/
  • The Japanese Breast Cancer Society. Practice guideline for breast cancer in 2015 [In Japanese]. Japan: Kanehara & Co., Ltd.; 2015
  • Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council [Internet]. Tokyo (Japan): Central Social Insurance Medical Council; [cited 2017 Feb 24]. Available from: http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000109789.pdf
  • Ryan M., Gerard K., Amaya-Amaya M. Using discrete choice experiments to value health and health care. Berlin (Germany): Springer Science & Business Media; 2007
  • National Health Insurance drug price list on 2017 Feb 15 [Internet]. Tokyo (Japan): Ministry of Health, Labour and Welfare; [cited 2017 Feb 24]. Available from: http://www.mhlw.go.jp/topics/2016/04/tp20160401-01.html
  • Fillingim RB, King CD, Ribeiro-Dasilva MC, et al. Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain 2009;10:447-85

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.